Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR 3.485
+0.285 (8.91%)
Aug 14, 2025, 3:44 PM CET
Paycor HCM Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue
14.09M
Revenue Growth
-38.24%
P/S Ratio
31.58
Revenue / Employee
121.50K
Employees
118
Market Cap
445.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.74B |
| Sartorius Stedim Biotech | 2.90B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 10.59M |
| Virbac | 1.40B |
Inventiva News
- 13 days ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 5 weeks ago - Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance - GlobeNewsWire
- 5 weeks ago - Inventiva receives $10 million milestone payment from CTTQ - GlobeNewsWire
- 6 weeks ago - Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease - GlobeNewsWire
- 2 months ago - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference - GlobeNewsWire
- 2 months ago - Inventiva S.A. reports Q1 results - Seeking Alpha
- 2 months ago - Inventiva reports 2025 First Quarter Financial Information¹ - GlobeNewsWire
- 2 months ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - Benzinga